November 29, 2016 - By kentuckypostne · 0 Comments
The stock of Cerecor Incorporated (NASDAQ:CERC) registered an increase of 16.42% in short interest. CERC’s total short interest was 158,100 shares in November as published by FINRA. Its up 16.42% from 135,800 shares, reported previously. With 221,300 shares average volume, it will take short sellers 1 days to cover their CERC’s short positions. The short interest to Cerecor Incorporated’s float is 2.38%. The stock closed at $5.09 during the last session. It is down 36.63% since April 26, 2016 and is uptrending. It has outperformed by 31.37% the S&P500.
Cerecor, Inc. is a clinical stage biopharmaceutical company. The company has a market cap of $46.97 million. The Firm is engaged in developing drug candidates for patients with neurological and psychiatric disorders. It currently has negative earnings. The Firm has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder ; CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Cerecor, Inc., incorporated on January 31, 2011, is a clinical stage biopharmaceutical company. The Firm is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Firm has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Firm owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme that is critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. The Company’s COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT found within the central nervous system. The Company’s COMTi platform includes compounds with varying degrees of selectivity of peripheral versus brain COMT inhibition, including some that work on both peripheral and brain COMT, and some that work primarily on brain COMT.
More notable recent Cerecor Inc (NASDAQ:CERC) news were published by: Marketwatch.com which released: “Cerecor Inc.” on November 22, 2013, also Businesswire.com with their article: “Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in …” published on August 29, 2016, Businesswire.com published: “Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and Former CEO of ACADIA …” on December 21, 2015. More interesting news about Cerecor Inc (NASDAQ:CERC) were released by: Reuters.com and their article: “BRIEF-Cerecor Inc – files for $75 million mixed shelf offering” published on November 08, 2016 as well as Businesswire.com‘s news article titled: “Cerecor Inc. Reports Second Quarter 2016 Financial Results” with publication date: August 15, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.